Berberine is a suppressor of Hedgehog signaling cascade in colorectal cancer

Sun, Qiang; Qiu, Tao; Ming, Tianqi; Tang, Shun; Zhao, Hui; Liu, Maolun; Ren, Shan; Lei, Jiarong; Liang, Yuanjing; Peng, Yu‐Hui; Wang, Minmin; Xu, Haibo

doi:10.1016/j.phymed.2023.154792

Cited by 39 publications

(15 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The plant kingdom contains many substances that may have the potential to prevent or treat human disease ( Zhao et al, 2022b ; Sun et al, 2023 ; Zhao et al, 2023 ), but these bioactive components (such as vitamins and alkaloids) usually show low bioavailability or biological instability. Recently, various techniques for improving drug delivery have been developed to solve the problems of bioavailability and stability.…”

Section: Clinical Applicationsmentioning

confidence: 99%

Armeniacae semen amarum: a review on its botany, phytochemistry, pharmacology, clinical application, toxicology and pharmacokinetics

Tang,

Wang,

Peng

et al. 2024

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Armeniacae semen amarum—seeds of Prunus armeniaca L. (Rosaceae) (ASA), also known as Kuxingren in Chinese, is a traditional Chinese herbal drug commonly used for lung disease and intestinal disorders. It has long been used to treat coughs and asthma, as well as to lubricate the colon and reduce constipation. ASA refers to the dried ripe seed of diverse species of Rosaceae and contains a variety of phytochemical components, including glycosides, organic acids, amino acids, flavonoids, terpenes, phytosterols, phenylpropanoids, and other components. Extensive data shows that ASA exhibits various pharmacological activities, such as anticancer activity, anti-oxidation, antimicrobial activity, anti-inflammation, protection of cardiovascular, neural, respiratory and digestive systems, antidiabetic effects, and protection of the liver and kidney, and other activities. In clinical practice, ASA can be used as a single drug or in combination with other traditional Chinese medicines, forming ASA-containing formulas, to treat various afflictions. However, it is important to consider the potential adverse reactions and pharmacokinetic properties of ASA during its clinical use. Overall, with various bioactive components, diversified pharmacological actions and potent efficacies, ASA is a promising drug that merits in-depth study on its functional mechanisms to facilitate its clinical application.

show abstract

Section: Clinical Applicationsmentioning

confidence: 99%

Armeniacae semen amarum: a review on its botany, phytochemistry, pharmacology, clinical application, toxicology and pharmacokinetics

Tang,

Wang,

Peng

et al. 2024

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the process of tumor deterioration, the disruption of the cell cycle leads to uncontrolled division, thereby endowing tumor cells with the ability to proliferate indefinitely. Given the association between cell cycle arrest and tumor tumorigenesis, the exploitation of anticarcinogens that target this procedure has drawn a biggish attention in the formulation of anticancer strategies (Sun et al, 2023).…”

Section: Arrest Cancer Cells Cyclementioning

confidence: 99%

Luteolin, a flavone ingredient: Anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researches

Shi,

Chen,

Gong

et al. 2023

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

Current pharmaceutical research is energetically excavating the pharmacotherapeutic role of herb‐derived ingredients in multiple malignancies’ targeting. Luteolin is one of the major phytochemical components that exist in various traditional Chinese medicine or medical herbs. Mounting evidence reveals that this phytoconstituent endows prominent therapeutic actions on diverse malignancies, with the underlying mechanisms, combined medication strategy, and pharmacokinetics elusive. Additionally, the clinical trial and pharmaceutical investigation of luteolin remain to be systematically delineated. The present review aimed to comprehensively summarize the updated information with regard to the anticancer mechanism, combined medication strategies, pharmacokinetics, clinical trials, and pharmaceutical researches of luteolin. The survey corroborates that luteolin executes multiple anticancer effects mainly by dampening proliferation and invasion, spurring apoptosis, intercepting cell cycle, regulating autophagy and immune, inhibiting inflammatory response, inducing ferroptosis, and pyroptosis, as well as epigenetic modification, and so on. Luteolin can be applied in combination with numerous clinical anticarcinogens and natural ingredients to synergistically enhance the therapeutic efficacy of malignancies while reducing adverse reactions. For pharmacokinetics, luteolin has an unfavorable oral bioavailability, it mainly persists in plasma as glucuronides and sulfate‐conjugates after being metabolized, and is regarded as potent inhibitors of OATP1B1 and OATP2B1, which may be messed with the pharmacokinetic interactions of miscellaneous bioactive substances in vivo. Besides, pharmaceutical innovation of luteolin with leading‐edge drug delivery systems such as host–guest complexes, nanoparticles, liposomes, nanoemulsion, microspheres, and hydrogels are beneficial to the exploitation of luteolin‐based products. Moreover, some registered clinical trials on luteolin are being carried out, yet clinical research on anticancer effects should be continuously promoted.

show abstract

“…Pancreatic adenocarcinoma, commonly referred to as pancreatic cancer, is a type of cancer that begins in the pancreas, an organ located deep within the abdomen ( 1 , 2 ). The pancreas plays a crucial role in digestion and blood sugar regulation by producing enzymes and hormones, such as insulin and glucagon ( 3 , 4 ). PAAD is a highly aggressive malignancy, exhibiting the poorest clinical outcome of all solid tumors.…”

Section: Introductionmentioning

confidence: 99%

CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma

Liu,

Li,

Han

2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundPancreatic adenocarcinoma (PAAD) is characterized by lower immunogenicity with a poor response rate to immune checkpoint inhibitors (ICIs) and exhibits the poorest prognosis of all solid tumors, which results in the highest tumor-related mortality among malignancies. However, the underlying mechanisms are poorly understood. In addition, diverse carbohydrate sulfotransferases (CHSTs), which are involved in the sulfation process of these structures, play an important role in the metastatic spread of tumor cells. Aberrant glycosylation is beginning to emerge as an influencing factor in tumor immunity and immunotherapy. Therefore, it might serve as a biomarker of the immunotherapeutic response in tumors. The purpose of the study was to evaluate the role of CHST12 in PAAD prognosis and its relevance to the immunotherapeutic response.MethodsA comprehensive investigation of the interactions between CHST12 expression and the immune microenvironment as well as the clinical significance of CHST12 in PAAD was conducted. Data derived from the Cancer Genome Atlas (TCGA) database were analyzed using univariate and multivariate approaches, the Tumor Immune Estimation Resource (TIMER), and Tumor Immune Dysfunction and Exclusion (TIDE) algorithms. Publicly available datasets were analyzed in this study. These data can be found on websites such as http://www.xiantao.love and https://www.proteinatlas.org. An assessment of the predictive value of CHST12 for PAAD prognosis was conducted using univariate and multivariate Cox regression analysis, Kaplan–Meier analysis, and nomograms. The TIMER algorithm calculates the proportions of six types of immune cells. The TIDE algorithm was used to indicate the characteristics of tumors that respond to ICI therapy.ResultsThe mRNA and protein levels of CHST12 showed the opposite trend. CHST12 mRNA expression was significantly upregulated in PAAD. According to Cox regression analysis, CHST12 RNA expression acts as a protective factor for overall survival [hazard ratio (HR), 0.617, P < 0.04]. Functional annotation indicated that CHST12-associated differentially expressed genes (DEGs) were related to the signaling activity of receptor tyrosine kinases and the regulation of ubiquitin-protein transferase. These are usually involved in tumor development and may be related to the treatment responses of immune checkpoint inhibitors (ICIs). There was significantly higher CHST12 mRNA expression in PAAD samples than in non-malignant samples.ConclusionsIn PAAD, elevated CHST12 mRNA expression might regulate immune cell infiltration into the tumor microenvironment (TME) and may predict clinical outcomes.

show abstract

Berberine is a suppressor of Hedgehog signaling cascade in colorectal cancer

Cited by 39 publications

References 43 publications

Armeniacae semen amarum: a review on its botany, phytochemistry, pharmacology, clinical application, toxicology and pharmacokinetics

Armeniacae semen amarum: a review on its botany, phytochemistry, pharmacology, clinical application, toxicology and pharmacokinetics

Luteolin, a flavone ingredient: Anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researches

CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma

Contact Info

Product

Resources

About